Langner, S., Staber, P.B., Schub, N., Gramatzki, M., Grothe, W., Behre, G., … Neumeister, P. (2008). Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplantation, 42, 275–279.
Palifermin was administered at 60 mcg/kg per day for three consecutive days before the initiation of conditioning therapy and again after graft infusion.
A group of 30 patients who had been treated with palifermin and undergone allogeneic hematopoietic stem-cell transplantation (HSCT) were retrospectively compared to a control group of 30 consecutive untreated patients receiving myeloablative conditioning.
The study was conducted from May 2005 to December 2006 in Austria and Germany.
The study was conducted within a compassionate use program.
The World Health Organization (WHO) Oral Toxicity Scale was used.